| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/82.13.1133 |
| P698 | PubMed publication ID | 1972761 |
| P2093 | author name string | Baas F | |
| Nooter K | |||
| Sonneveld P | |||
| Herweijer H | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| cyclosporine | Q367700 | ||
| P304 | page(s) | 1133-1140 | |
| P577 | publication date | 1990-07-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine | |
| P478 | volume | 82 |
| Q54249265 | A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. |
| Q41169397 | Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study |
| Q54163191 | Analysis of MDR1 and MDR3 multidrug resistance gene expression and amplification in consecutive samples in patients with acute leukaemias. |
| Q54255343 | Analysis of multidrug‐resistance (MDR‐1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma |
| Q43285192 | Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis |
| Q40708934 | Cellular models for multiple drug resistance in cancer |
| Q72852195 | Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion |
| Q40596146 | Cellular resistance to cancer chemotherapy. |
| Q54254503 | Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3. |
| Q41660599 | Co-amplification and over-expression of twomdrgenes in a multidrug-resistant human colon carcinoma cell line |
| Q43622754 | Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial |
| Q35615329 | Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression |
| Q43885601 | Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). |
| Q54233093 | Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemia. |
| Q54259184 | Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression |
| Q54280292 | Drug resistance in oncology: from concepts to applications. |
| Q34099716 | Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. |
| Q40860163 | Evaluating limited specificity of drug pumps reduced relative resistance in human MDR phenotypes |
| Q41525074 | Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies |
| Q38512228 | Exposure to lipophilic industrial solvents leads to increased P-glycoprotein expression in peripheral blood cells |
| Q54307223 | Expression of mdr1 and mdr3 multidrug-resistance genes in hairy cell leukaemia |
| Q54180477 | Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. |
| Q54722687 | Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. |
| Q67521629 | Expression of p170 protein in multiple myeloma: a clinical study |
| Q73337926 | Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias |
| Q54263700 | Flow cytometric analysis of P-glycoprotein in normal and leukemic cells |
| Q54166914 | Flow cytometric assessment of the cellular pharmacokinetics of fluorescent drugs |
| Q41707309 | Flow cytometric double labeling technique for screening of multidrug resistance |
| Q41392317 | Genes and chromosomes in chronic B-cell leukemia |
| Q54194573 | High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. |
| Q47683128 | Imaging Multidrug Resistance in Hematological Malignancies |
| Q43078241 | Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. |
| Q37658682 | Importance of drug transporters in pharmacokinetics and drug safety |
| Q54281368 | In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. |
| Q41262102 | Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome |
| Q54017376 | MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. |
| Q41606250 | Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias |
| Q33758413 | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) |
| Q37085507 | Modern chemotherapeutic regimens in the management of aggressive non-Hodgkin lymphoma: Can they be improved? |
| Q41142663 | Modulation of multidrug resistance in multiple myeloma |
| Q41176359 | Molecular mechanisms of multidrug resistance in cancer chemotherapy |
| Q58136246 | Multidrug Resistance |
| Q47682837 | Multidrug Resistance in Acute Leukaemia: A Comparative Study of Immunocytochemical and RNA Slot Blot Detection of P-glycoprotein Expression |
| Q40535284 | Multidrug resistance (MDR) genes in haematological malignancies |
| Q36495579 | Multidrug resistance (mdr) genes in human cancer |
| Q35166741 | Multidrug resistance in acute leukemia: a conserved physiologic function |
| Q41055142 | Multidrug resistance in acute myeloid leukaemia |
| Q38144200 | Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? |
| Q41518805 | Multidrug resistance in rat colon carcinoma cell lines CC531, CC531mdr+ and CC531rev |
| Q37706888 | Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients |
| Q41132533 | Multidrug resistance-associated protein (MRP) in haematological malignancies |
| Q41292266 | Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line |
| Q24562993 | New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein |
| Q40597143 | On-line flow cytometry: a versatile method for kinetic measurements. |
| Q53718643 | P-Glycoprotein Expression in Drug-Resistant Chronic Lymphoproliferative Disorder. |
| Q73481268 | P-glycoprotein expression in cartilaginous tumors |
| Q50918570 | P-glycoprotein expression in de novo acute myeloid leukemia. |
| Q53396986 | P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols |
| Q46293717 | P-glycoprotein is expressed in the mineralizing regions of the skeleton |
| Q40380366 | P-glycoprotein: clinical significance and methods of analysis |
| Q40958072 | P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance |
| Q53024621 | PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia |
| Q41612022 | Preparation and characterization of a murine monoclonal antibody (MDR3M) reactive with mdr3 gene product |
| Q48011141 | Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia |
| Q35994137 | Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia |
| Q35796217 | Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study |
| Q44167866 | Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukemia. |
| Q58032690 | Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine |
| Q41649875 | Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype |
| Q41597554 | The P-glycoprotein multidrug transporter |
| Q33490842 | The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. |
| Q54299681 | The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia |
| Q44005151 | The multiple drug resistance gene, MDR1: expression at the protein and RNA levels |
| Q54166246 | Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rhl23) to determine transduction frequency and in vivo selection |
| Q78156200 | Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia |
| Q37963498 | Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies |
| Q41055102 | Treatment and prognostic factors in acute myeloid leukaemia |
Search more.